ReviewNanomedicine : nanotechnology, biology, and medicine2015
Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases.
Review in Nanomedicine : nanotechnology, biology, and medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Eco-friendly synthesis of silver nanoparticles from the leaf blades extract of seagrass Thalassia hemprichii: Multifunctional agents for biomedical and environmental applications.Journal, genetic engineering & biotechnology · 2025Article
- Strategies in Parkinson's Disease Therapeutics - A Need for Synergy of Ayurveda, Small Molecules and Nanoparticles aided Approaches.Current topics in medicinal chemistry · 2025Review
- Nanotechnology-powered Meningitis Therapies: Lipid Nanoparticles Lead the Way.Current pharmaceutical biotechnology · 2025Review
- Biocompatible and bioactivable terpolymer-lipid-MnOMaterials today. Bio · 2024Article
- Aggregation-Inhibiting scFv-Based Therapies Protect Mice against AAV1/2-Induced A53T-α-Synuclein Overexpression.Biomolecules · 2023Article
- Recent Advancements in Nanomaterials: A Promising Way to Manage Neurodegenerative Disorders.Molecular diagnosis & therapy · 2023Review
- Polymersomes Based Versatile Nanoplatforms for Controlled Drug Delivery and Imaging.Advanced pharmaceutical bulletin · 2023Review
- Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders.Molecules (Basel, Switzerland) · 2023Review
- Article
- Stem Cell-based and Advanced Therapeutic Modalities for Parkinson's Disease: A Risk-effectiveness Patient-centered Analysis.Current neuropharmacology · 2022Review
- Advancement of nanomedicines in chronic inflammatory disorders.Inflammopharmacology · 2022Review
- Targeting neuroinflammation by intranasal delivery of nanoparticles in neurological diseases: a comprehensive review.Naunyn-Schmiedeberg's archives of pharmacology · 2022Review
- Serum Albumin Nanoparticles: Problems and Prospects.Polymers · 2021Review
- Perspective Insights to Bio-Nanomaterials for the Treatment of Neurological Disorders.Frontiers in bioengineering and biotechnology · 2021Review
- Immunopathogenesis of Craniotomy Infection and Niche-Specific Immune Responses to Biofilm.Frontiers in immunology · 2021Review
- Plant-Based Synthesis of Zinc Oxide Nanoparticles (ZnO-NPs) Using Aqueous Leaf Extract ofOxidative medicine and cellular longevity · 2021Article
- The Role of Natural Compounds and their Nanocarriers in the Treatment of CNS Inflammation.Biomolecules · 2020Review
- A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems.RSC advances · 2020Review
- Therapeutic Nanoparticles and Their Targeted Delivery Applications.Molecules (Basel, Switzerland) · 2020Review
- Biomaterials in Neurodegenerative Disorders: A Promising Therapeutic Approach.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Interest in nanoneuromedicine has grown rapidly due to the immediate need for improved biomarkers and therapies for psychiatric, developmental, traumatic, inflammatory, infectious and degenerative nervous system disorders. These, in whole or in part, are a significant societal burden due to growth in numbers of affected people and in disease severity. Lost productivity of the patient and his or her caregiver, and the emotional and financial burden cannot be overstated. The need for improved health care, treatment and diagnostics is immediate. A means to such an end is nanotechnology. Indeed, recent developments of health-care enabling nanotechnologies and nanomedicines range from biomarker discovery including neuroimaging to therapeutic applications for degenerative, inflammatory and infectious disorders of the nervous system. This review focuses on the current and future potential of the field to positively affect clinical outcomes. From the clinical editor: Many nervous system disorders remain unresolved clinical problems. In many cases, drug agents simply cannot cross the blood-brain barrier (BBB) into the nervous system. The advent of nanomedicines can enhance the delivery of biologically active molecules for targeted therapy and imaging. This review focused on the use of nanotechnology for degenerative, inflammatory, and infectious diseases in the nervous system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.